active ingredient semaglutide | C187H291N45O59 | CID 56843331 Troubling Findings in Study of

Chronic hypoxia has been suggested as a unifying pathway leading to kidney failure [8] and blood oxygen level-dependent MRI (BOLD-MRI) has emerged as a new non-invasive method for quantifying oxygenation in the kidneys [9]

How to Store Properly : Keep the vial in the refrigerator but not in the freezer

Additional important safety considerations include: Risk of hypoglycaemia when combined with insulin or sulfonylureas Potential for dehydration and acute kidney injury from severe gastrointestinal symptoms Increased risk of diabetic retinopathy complications with rapid glucose lowering, particularly with semaglutide Importantly, memory loss or cognitive impairment is not listed among the recognised adverse effects in the Summary of Product Characteristics (SmPC) for any GLP-1 receptor agonist licensed in the UK

STEP 2 : Specifically examined adults with type 2 diabetes and obesity, showing mean weight reduction of 9.6% with semaglutide 2.4 mg versus 3.4% with placebo, alongside significant improvements in HbA1c levels